Please login to the form below

Not currently logged in
Email:
Password:

Invega Trinza

This page shows the latest Invega Trinza news and features for those working in and with pharma, biotech and healthcare.

J&J files three-monthly schizophrenia drug in Europe

J&J files three-monthly schizophrenia drug in Europe

The three-monthly version was approved by the FDA as Invega Trinza in May on the back of clinical data showing that the drug was effective, preventing significant return of schizophrenic ... Xeplion/Invega Sustenna is already a big earner for J&J, with

Latest news

  • FDA approves J&J’s schizophrenia drug Invega Trinza FDA approves J&J’s schizophrenia drug Invega Trinza

    The FDA has approved Johnson &Johnson's Invega Trinza (three-month paliperidone palmitate) for schizophrenia. ... Recovery looks different for everyone and the long-term symptom control offered by Invega Trinza can help patients work toward their own

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Consulting at McCann Health

We are the strategic consultancy of McCann Health. We combine fresh and creative thinking with scientific and strategic depth...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics